Best deal of the week



Instruction for use: Phlogenzym

I want this, give me price

Dosage form: Tablets; Enteric coated tablets


L03AX Other immunostimulants

Pharmacological groups:

Anti-inflammatory, immunomodulating agent [Enzymes and antiferments]

Anti-inflammatory, immunomodulating agent [Other non-narcotic analgesics, including non-steroidal and other anti-inflammatory drugs]

Anti-inflammatory, immunomodulating agent [Other immunomodulators]

The nosological classification (ICD-10)

B19 Viral hepatitis, unspecified: Anemia without hepatitis; Viral hepatitis; Viral hepatitis in children; Infection of the liver; Acute liver infection

G35 Multiple Sclerosis: Disseminated Sclerosis; Multiple sclerosis; Recurrent multiple sclerosis; Secondary-progressive multiple sclerosis; Exacerbation of multiple sclerosis; Mixed forms of multiple sclerosis

I22 Subsequent myocardial infarction: Atherosclerosis and the likelihood of reinfarction; Myocardial infarction re; Relapses myocardial infarction

I20 Angina [angina]: Heberden disease; Angina pectoris; The attack of angina pectoris; recurrent angina; Spontaneous angina; Stable angina pectoris; Angina rest; Angina progressing; Angina mixed; Angina spontaneous; stable angina; Chronic stable angina; Angina Syndrome X

I25.9 Chronic ischemic heart disease, unspecified: CHD; Insufficiency of coronary circulation; Coronary atherosclerosis in patients with coronary artery disease

I63 Cerebral infarction: ischemic Stroke; Ischemic brain disease; Ischemic stroke; Ischemic stroke and its consequences; Ischemic cerebral stroke; Ischemic cerebrovascular accident; Ischemic brain damage; Ischemic brain damage; ischemic conditions; Cerebral ischemia; Acute hypoxia brain; Acute cerebral ischemia; Acute ischemic cerebrovascular accident; Acute cerebral infarction; Acute ischemic stroke; Acute period of ischemic stroke; Focal cerebral ischemia; Ischemic stroke; recurrent stroke; The syndrome of Morgagni-Adams-Stokes; Chronic cerebral ischemia; cerebrovascular stroke; embolic stroke; Ischemic brain damage

I70.2 Atherosclerosis of arteries: arteriosclerosis obliterans; Arteriosclerosis peripheral arteries; Atherosclerosis of the arteries of the lower extremities; Atherosclerosis of peripheral arteries; Atherosclerosis limbs; Occlusive disease of the lower extremities; arteriosclerosis obliterans; Arteriosclerosis obliterans of lower limb arteries; Atherosclerosis obliterans of the upper limbs; Arteriosclerosis obliterans of lower extremities; Atherosclerosis of arteries; limb arteriopathy; Arteriosclerosis obliterans limbs; arteriosclerosis obliterans

I74 Embolism and arterial thrombosis: Thrombosis of effort (stress); Arterial thrombosis; Arteriothrombosis; Subacute and chronic arterial thrombosis; Subacute thrombosis of peripheral arteries; Postoperative thrombosis; Vascular thrombosis; Vascular embolism; Thrombosis of aortocoronary shunt; Arterial thrombosis; Thrombosis of arteries; Coronary artery thrombosis; Coronary thrombosis; Thrombosis of blood vessels; Thrombosis with ischemic stroke; Thrombosis with general surgical operations; Thrombosis in Oncology Operations; Vascular thrombosis; Thrombus formation in the postoperative period; Thrombotic complications; Thromboembolic diseases; Thromboembolic syndrome; Thromboembolic complication in the postoperative period; Thromboembolism of arteries; Partial vascular thrombosis; Embolism; Embolism of arteries

I79.8 Other disorders of arteries, arterioles and capillaries in diseases classified elsewhere: Atherosclerotic occlusive lesions of peripheral arteries; Disturbances of microcirculation; Disorders of microcirculation; Obstruction in the coronary circulation system

I80.0 Phlebitis and thrombophlebitis of superficial vessels of lower limbs: Thrombophlebitis of superficial veins; Thrombophlebitis of superficial veins of legs; Thrombophlebitis of superficial veins; Phlebitis of superficial veins of legs; Inflammation of veins

I87.0 Postphlebitic syndrome: post-thrombotic venous insufficiency; Postthrombotic disease; Post thrombophlebitic syndrome; Post-thrombophlebitis; Post-thrombophlebitic syndrome; Postphlebitic syndrome; Post thrombotic syndrome; Postphlebitic syndrome (stasis syndrome)

I89.0 Lymphocyte, not elsewhere classified: Venous-lymphatic insufficiency; Lymphatic edema; Lymphedema; Lymphostasis; Lymphostasis and swelling after treatment of breast cancer; Lymphangiectatic edema; Lymphatic edema; Chronic lymphostasis; Lymphodema

J18 Pneumonia without specification of pathogens: Alveolar pneumonia; Community-acquired pneumonia atypical; Community-acquired pneumonia non-pneumococcal; Pneumonia; Inflammation of the lower respiratory tract; Inflammatory lung disease; Shared pneumonia; Respiratory and lung infections; Infections of the lower respiratory tract; Cough with inflammatory diseases of the lungs and bronchi; Croupous pneumonia; Nosocomial pneumonia; Exacerbation of chronic pneumonia; Acute community-acquired pneumonia; Acute pneumonia; Focal pneumonia; Pneumonia abscessing; Pneumonia bacterial; Pneumonia croupy; Pneumonia of focal; Pneumonia with difficulty in sputum discharge; Pneumonia in AIDS patients; Pneumonia in children; Septic pneumonia; Chronic Obstructive Pneumonia; Chronic pneumonia; Lymphoid interstitial pneumonia

J44 Other chronic obstructive pulmonary disease: Allergic bronchitis; Bronchitis allergic; Asthmatic bronchitis; Bronchitis obstructive; Disease of the bronchi; Difficult sputum separation in acute and chronic respiratory diseases; Cough with inflammatory diseases of the lungs and bronchi; Reversible bronchial obstruction; Reversible obstructive airway disease; Obstructive bronchial disease; Obstructive pulmonary disease; Obstructive bronchitis; Spastic bronchitis; Chronic lung diseases; Chronic nonspecific lung diseases; Chronic Obstructive Pulmonary Diseases; Chronic obstructive bronchitis; Chronic obstructive airways disease; Chronic obstructive pulmonary disease; Restrictive pathology of the lungs

K10.2 Inflammatory diseases of jaws: Infections of maxillofacial area; Purulent-inflammatory processes of maxillofacial area

K76.9 Liver disease, unspecified: Change in liver function in heart failure; Restoration of impaired liver function; Severe liver function disorders; Hepatitis; Hepatosis; Hepatopathy; Liver dysfunction; Diseases of the liver; Impaired liver function; Dysfunction of the liver; Infringements of function of a liver of an inflammatory etiology; Functional liver failure; Functional disorders of the liver; Chronic liver disease; Chronic diffuse liver disease; Enterogenic diseases of the gallbladder and liver

L91.0 Keloid scar: Hyperlusculation; Keloid; Keloid scar; Keloid scars

M02 Reactive arthropathies: Reactive arthritis

M35.3 Rheumatic polymyalgia: Rhizomelous pseudoarthritis; Rheumatic polymyalgia; Pain syndrome in rheumatic diseases; Muscle pain with rheumatism; Extra-articular rheumatism; Extra-articular rheumatic syndrome; Extra-articular rheumatic diseases; Extra-articular rheumatic lesions of soft tissues; Extra-articular forms of rheumatism; Rheumatic soft tissue damage; Rheumatism of soft tissues; Rheumatic diseases of soft tissues; Rheumatic diseases of the periarticular soft tissues; Rheumatic affections of soft tissues; Rheumatic collagen diseases

M45 Ankylosing spondylitis: Ankylosing spondylarthrosis; Marie-Strumpel disease; Ankylosing spondylitis; Ankylosing spondylitis; Pain syndrome in acute inflammatory diseases of the musculoskeletal system; Pain syndrome in chronic inflammatory diseases of the musculoskeletal system; Bechterew's disease; Ankylosing spondylitis; Diseases of the spinal column; Rheumatic spondylitis; Bechterew-Marie-Strumpel disease

N30.9 Cystitis, unspecified: Cystitis, complicating bladder tumors

N34 Urethritis and urethral syndrome: Urethral buzhirovanie; Gonococcal urethritis; Urethrocystitis; Gonorrheic urethritis; Urethritis; Non-gonococcal urethritis; Negative urethritis; Lesion of the urethra; Acute gonococcal urethritis; Acute gonorrhea urethritis; Acute urethritis; Infection of the urethra; Bacterial nonspecific urethritis; Bacterial urethritis

N39.0 Urinary tract infection without established localization: Fungal infections of the urinary tract; Asymptomatic bacteriuria; Bacterial infections of the urinary tract; Bacterial infections of the urinary tract; Bacterial infections of the genitourinary system; Bacteriuria; Bacteriuria asymptomatic; Bacteriuria chronic latent; Asymptomatic bacteriuria; Asymptomatic massive bacteriuria; Inflammatory urinary tract disease; Inflammatory urinary tract disease; Inflammatory diseases of the bladder and urinary tract; Inflammatory diseases of the urinary system; Inflammatory diseases of the urinary tract; Inflammatory diseases of the urogenital system; Fungal diseases of the urogenital tract; Urinary Tract Infections; Urinary Tract Infections; Infections of the urinary system; Urinary tract infections; Urinary Tract Infections; Urinary tract infections caused by enterococci or mixed flora; Urinary tract infections uncomplicated; Urinary tract infections complicated; Infections of the urogenital system; Infections urogenital; Infectious diseases of the urinary tract; Urinary Tract Infection; Urinary tract infection; Urinary system infection; Urinary tract infection; Urinary tract infection; Infection of the urogenital tract; Uncomplicated urinary tract infections; Uncomplicated urinary tract infections; Uncomplicated urinary tract infections; Uncomplicated infections of the genitourinary system; Exacerbation of chronic urinary tract infection; Retrograde kidney infection; Recurrent urinary tract infections; Recurrent urinary tract infections; Recurrent infectious diseases of the urinary tract; Mixed urethral infections; Urogenital infection; Urogenital Infectious-Inflammatory Disease; Urogenital mycoplasmosis; Urologic disease of infectious etiology; Chronic urinary tract infection; Chronic inflammatory diseases of the pelvic organs; Chronic urinary tract infections; Chronic infectious diseases of the urinary system

N41.9 Inflammatory disease of prostate, unspecified

N70 Salpingitis and oophoritis: Adnexitis; Inflammatory diseases of female genitalia; Inflammatory diseases of female genital organs; Infection of the genitals; Oophoritis; Acute adnexitis; Salpingitis; Salpingo-oophoritis; Chronic inflammatory diseases of the ovaries; Inflammation of the ovaries

N95.1 menopausal and menopausal status of women: Atrophy of the mucosa of the lower genital tract, caused by estrogen deficiency; Vaginal dryness; Autonomic dysfunction in women; gipoestrogeniya state; Deficiency of estrogen in menopausal women; Degenerative changes of the mucous membrane in the menopause; Natural menopause; an intact uterus; climacteric; Menopause women; Menopause in women; menopausal depression; Climacteric ovarian dysfunction; Menopause; Climacteric neurosis; Menopause; Menopausal symptoms complicated psychovegetative; Climacteric syndrome; Climacteric vegetative disorders; Climacteric psychosomatic disorder; menopausal disorders; Menopausal disorders in women; menopausal condition; Climacteric vascular disorders; Menopause; Menopausal vasomotor symptoms; menopausal period; Lack of estrogen; Feeling the heat; Pathological menopause; perimenopause; menopause; postmenopausal; Premature menopause; premenopauznom period; tides; hot flashes; flushing in the Meno and postmenopausal; Hot flashes / hot flashes in menopause; Heart attack during menopause; Early menopause in women; Disorders of menopause; climacteric syndrome; Vascular complications of menopause; Physiological menopause; Estrogendefitsitnye state; premature Menopause

N99.4 Postoperative adhesions in the pelvis: Adhesive disease

T02.9 Multiple fractures, unspecified: Fracture of bones

T14.9 Injury unspecified: Pain syndrome after trauma; Pain syndrome with injuries; Pain syndrome with injuries and after surgery; Pain in case of injury; Pain of a traumatic nature; Joint pain with injuries; Postoperative and post-traumatic pain; Pain in case of injury; Pain of traumatic origin; Severe pain syndrome of traumatic origin; Deep tissue damage; Deep scratches on the trunk; Closed injury; Minor Household Injuries; Minor skin damage; Violations of the integrity of soft tissues; Uncomplicated trauma; Extensive traumatic injury; Acute pain syndrome of traumatic origin; Edema with trauma; Postponed sports injuries; Post-traumatic pain; Soft tissue injuries; Joint wounds; Sports injuries; Injury; Traumatic pain; Traumatic pains; Traumatic infiltrate; Injuries to sports

T30 Thermal and chemical burns of unspecified site: Pain syndrome with burns; Pain in burns; Pain with burns; Sluggishly healing post-burn wounds; Deep burns with a wet scab; Deep burns with abundant compartments; Deep burn; Laser burn; Burn; Burn of rectum and perineum; Burn with mild exudation; Burn disease; Burn injury; Superficial burn; Superficial burn of I and II degree; Superficial skin burns; After-burn trophic ulcer and wound; Post-burn complication; Loss of fluid in burns; Sepsis burn; Thermal burns; Thermal skin lesions; Thermal burn; Trophic after-burn ulcers; Chemical burn; Surgical burn

T79.3 Post-traumatic wound infection, not elsewhere classified: Inflammation after surgery and trauma; Inflammation after trauma; Secondary infection of skin and mucous membrane damage; Deep Wounds; Purulent wound; Purulent-necrotic phase of wound process; Purulent-septic diseases; Purulent Wounds; Purulent wounds with the presence of deep cavities; Granulating wounds of small size; Disinfection of purulent wounds; Wound infections; Infections wound; Infection of wounds; Infected and non-healing wound; Infected postoperative wound; Infected wound; Infected Skin Wounds; Infected burns; Infected Wounds; Suppurating postoperative wounds; Extensive purulent-necrotic process of soft tissues; Burn infections; Burn infection; Perioperative infection; Poorly healing infected wound; Postoperative and purulent-septic wound; Postoperative wound infection; Wound infection; Wound botulism; Wound infections; Wounds of purulent; Wounds infected; Reinfection of granulating wounds; Sepsis posttraumatic

T84.5 Infection and inflammatory response due to endoprosthetics

Z100 * CLASS XXII Surgical practice: Abdominal surgery; adenomectomy; Amputation; Coronary angioplasty; Angioplasty of the carotid arteries; Antiseptic skin treatment for wounds; Antiseptic Hand; Appendectomy; atherectomy; Balloon coronary angioplasty; Vaginal hysterectomy; The coronary bypass; Interventions in the vagina and cervix; Interventions on the bladder; Intervention in the mouth; Restoration and reconstructive surgery; Hand hygiene of medical personnel; Gynecologic surgery; Gynecological intervention; Gynecological surgery; Hypovolemic shock during operations; Disinfection of purulent wounds; Disinfection of wounds edges; Diagnostic intervention; Diagnostic procedures; Cervical Diathermocoagulation; Long-surgery; Replacing the fistula catheters; Infection in orthopedic surgery; Artificial heart valve; cystectomy; Short-term outpatient surgery; Short-term operation; Short surgical procedures; Krikotireotomiya; Blood loss during surgery; Bleeding during surgery and in the postoperative period; Kuldotsentez; laser photocoagulation; laser coagulation; retinal laser coagulation; Laparoscopy; Laparoscopy in Gynecology; CSF fistula; Small gynecological operations; Small surgical procedures; Mastectomy and subsequent plastic; mediastinotomy; Microsurgical operations on the ear; Mukogingivalnye operation; suturing; Minor surgery; neurosurgical operation; Immobilization of the eyeball in ophthalmic surgery; testectomy; pancreatectomy; Perikardektomiya; The period of rehabilitation after surgery; The period of convalescence after surgery; Percutaneous transluminal coronary angioplasty; Pleural thoracentesis; Pneumonia postoperative and posttraumatic; Preparation for surgical procedures; Preparation for surgery; Preparation of the surgeon's hands before surgery; Preparation of the colon for surgical procedures; Postoperative aspiration pneumonia in neurosurgical and thoracic surgery; Postoperative nausea; Postoperative bleeding; postoperative granuloma; postoperative shock; The early postoperative period; myocardial revascularization; Radiectomy; gastric Resection; bowel resection; uterine Resection; liver Resection; enterectomy; Resection of part of the stomach; Reocclusion of the operated vessel; Bonding tissues during surgical procedures; Removal of sutures; Condition after eye surgery; Condition after surgery; Condition after surgery in the nasal cavity; Condition after gastrectomy; Status after resection of the small intestine; Condition after tonsillectomy; Condition after removal of the duodenum; Condition after phlebectomy; Vascular surgery; Splenectomy; Sterilization of surgical instruments; Sterilization of surgical instruments; sternotomy; Dental surgery; Dental intervention in periodontal tissues; strumectomy; Tonsillectomy; Thoracic surgery; Thoracic surgery; total gastrectomy; Transdermal intravascular coronary angioplasty; Transurethral resection; Turbinektomiya; Removal of a tooth; cataract surgery; Removal of cysts; tonsillectomy; Removal of fibroids; Removing the mobile primary teeth; Removing polyps; Removing broken tooth; Removal of the uterus body; Removal of sutures; Fistula likvoroprovodyaschih ways; Frontoetmoidogaymorotomiya; Surgical infection; Surgical treatment of chronic limb ulcers; Surgery; The surgery in the anal area; The surgery on the colon; Surgical practice; The surgical procedure; Surgical interventions; Surgery on the gastrointestinal tract; Surgical procedures on the urinary tract; Surgical procedures on the urinary system; Surgical intervention of the genitourinary system; Surgical procedures on the heart; Surgical manipulation; surgery; Surgery on the veins; Surgical intervention; Vascular surgery; Surgical treatment of thrombosis; Surgery; cholecystectomy; Partial gastric resection; hysterectomy; Percutaneous transluminal coronary angioplasty; Percutaneous transluminal angioplasty; Coronary artery bypass; tooth Extirpation; Extirpation of milk teeth; pulpectomy; pulsative cardiopulmonary bypass; tooth Extraction; teeth Extraction; cataract extraction; Electrocoagulation; endourological intervention; episiotomy; Etmoidotomiya; Complications after tooth extraction

Z54.0 Recovery period after surgical intervention: Conditions after neurosurgical operations; Conditions after removal of gallstones; Conditions after surgery; Restorative period after surgical interventions; Recovery period after operations; The rehabilitation period after surgical interventions; The rehabilitation period after surgical operations; Reconvalence after surgery; Reconvalence after surgical intervention; Reconvalescence in the postoperative period; Recovery period after surgery in front of eyes; Period after hemorrhoidectomy; Postoperative period; Period of postoperative rehabilitation; The rehabilitation period after injuries

Z96.5 Presence of implants of the roots of the teeth and jaw: Implantation of artificial dental roots

Z96.7 Presence of implants of other bones and tendons


Tablets, covered with enteric-coated shell 1 tab.

Active substances: Bromelain 450 units (FIP)

Trypsin 1440 units (FIP) (24 μkat)

Rutin (rutozide) 100 mg

Auxiliary substances: lactose monohydrate - 148.58 mg; Cornstarch - 24 mg; Magnesium stearate - 12.72 mg; Stearic acid - 11.28 mg; Purified water - 6.6 mg; Silicon dioxide colloidal - 6.36 mg; Talc - 2.46 mg

Shell: methacrylic acid and methyl methacrylate copolymer (1: 1) - 11.89 mg; Macrogol 6000 - 0.67 mg; Talc - 4.08 mg; Triethyl citrate 1.2 mg; Vanillin - 0.15 mg

Description of dosage form

The biconvex tablets are round in shape, coated with a smooth surface of a greenish-yellow color, a characteristic odor; Minor deviations from homogeneity of color are admissible: marble pattern, dot blotches.

The core of the tablet is light yellow in cross section, tuberose, and the coat is light yellow in color.

Pharmachologic effect

Mode of action - anti-inflammatory, immunomodulating.


PHLOGENZYM is a new generation medicinal preparation consisting of a combination of highly active proteolytic enzymes (enzymes) of plant and animal origin, bromelain and trypsin in combination with routine. In combination, the enzymes exert a pleiotropic (multiple) action, having a variety of pharmacological actions on pathophysiological and biochemical processes. Enzymes of the drug realize their therapeutic effects through anti-inflammatory, immunomodulating, antiaggregant, fibrinolytic, thrombolytic, decongestant and secondary analgesic actions. The tablets of the drug, coated with an enteric coating, transitively pass the upper sections of the digestive tract, not injuring the stomach, are absorbed in the small intestine by resorption of intact molecules (endocytosis, pinocytosis). Proteases of the drug, binding to blood transport proteins (α-2-macroglobulin and α-1-antitrypsin) form a reversible protease-antiprotease complex in which the antigenic determinants of exogenous proteases of the drug are masked, which prevents allergic reactions. As a result of formation of a complex with enzymes, antiprotease (α-2-macroglobulin) passes into the active form, which serves as an extracellular regulator of pro-inflammatory cytokines and growth factors, carrying out their transfer, clearance and elimination.

The formation of an active protease-antiprotease complex allows the proteolytic enzymes to be safely moved along the vascular bed to the inflammatory focus and to the site of injury, regardless of the site of localization in the body. The complex keeps and slows the removal of proteolytic enzymes of the drug from the body, increases the time of their circulation in the vascular bed and, accordingly, the therapeutic effect. Getting into the inflammatory focus and wounds, proteolytic enzymes break down (hydrolyse) damaged proteins, tissues and eliminate (remove) cellular debris (detritus), contributing to the acceleration of cleansing and healing of the wound.

The drug positively affects the course of the inflammatory process, modulates the protective reactions of the body, which contributes to the physiological course of inflammation at different stages. Proteolytic enzymes of the drug accelerate the decomposition of inflammatory mediators, cleave immune complexes and membrane deposits, increase the activity of phagocytes, natural killer cells, stimulate interferonogenesis. Protease drugs reduce the level of proinflammatory cytokines (IL-1β, IL-6, IL-8, INF-γ, TNF-α) and promote the production of anti-inflammatory cytokines (including IL-4, IL-10), regulate the level Ig and antibodies of blood. Enzymes of the drug limit the pathological manifestations of autoimmune and immunocomplex processes, restore the immunological reactivity of the organism.

Protease drugs reduce the level of the transforming growth factor β, the increase of which leads to excessive scarring. Proteolytic enzymes have a regulatory effect on the synchronization of the formation of the basement membrane (laminin), the modulation of the wound process and the expression of angiogenesis factors (vasculoendothelial growth factor, fibroblast growth factor and a number of other factors). Thus, the enzymes of the drug contribute to the improvement of reparative processes, the prevention of the formation of hypertrophic and keloid scars, the development of adhesions after surgical interventions on the abdominal cavity.

Enzymes of the drug cleave and remove damaged tissues, accelerate resorption of hematomas and edema due to normalization of vascular wall permeability, reduction of infiltration of interstitium by plasma proteins, increase in elimination of protein detritus and fibrin deposits, improvement of microcirculation and trophic processes in the area of injury. Optimization of the inflammatory process by proteolytic enzymes due to reduction of oncotic pressure and edema of tissues, reduction of pressure on nerve endings, elimination of ischemia and normalization of microcirculation, direct proteolysis of inflammatory mediators allows proteases to exert a secondary analgesic effect. Simultaneously, proteolytic enzymes provide stimulation of healing and repair processes, reduce the risk of thromboembolic complications with prolonged immobilization, prevent the development of trophic disorders and suppurative complications.

Enzymes of the drug positively affect the improvement of microcirculation, increase the delivery of oxygen and nutrients to the wound, reduce inflammation in the lesion, maintain the physiological process of regeneration and accelerate the restoration of the function of organs and tissues.

The drug improves the rheological properties of blood (viscosity and fluidity) due to the positive effect on the functional state of blood cells and the vascular wall, the plasticity (deformability) of erythrocytes, stabilization of the permeability of the endothelium, increased fibrinolytic activity of blood serum, a decrease in the density of adhesive molecules, a decrease in aggregation (adhesion) of platelets.

Proteolytic enzymes of the drug increase the effectiveness of antibiotics while reducing unwanted effects of antibiotic therapy (dysbiosis, irritable bowel syndrome). Proteases improve the cleavage of substrates, optimize the balance of microbiota, contribute to the restoration of endoecology of the intestine.

Indication of the Phlogenzym

In complex therapy and prevention of the following diseases and conditions:

Surgery - postoperative recovery and rehabilitation of patients (improvement of reparative processes and regeneration), postoperative purulent-inflammatory complications, prevention of adhesion and keloid scar formation, reduction of the risk of thromboembolic complications during prolonged immobilization;

Traumatology - fractures of bones, injuries of tendons and ligaments, bruises and hematomas of soft tissues, sports injuries, burns, better integration of endoprostheses, osteosynthesis;

Angiology - acute deep vein thrombosis, superficial vein thrombophlebitis, postthrombotic disease, obliterating atherosclerosis of lower extremity arteries and other chronic angiopathies, microcirculatory disorders, lymphatic edema (lymphedema);

Urology - acute and chronic inflammation of the urinary tract (cystitis, urethritis, cystopyelitis, prostatitis);

Gynecology - acute and chronic inflammatory diseases of the pelvic organs (adnexitis, salpingoophoritis), vascular complications of the climacteric period, a decrease in the frequency and severity of complications of hormone replacement therapy;

Cardiology - IHD, prevention of angina attacks, reduced risk of vascular accidents and repeated heart attacks;

Gastroenterology - hepatitis;

Rheumatology - rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, rheumatic soft tissue damage;

Neurology - ischemic stroke, multiple sclerosis;

Pulmonology - pneumonia, chronic obstructive pulmonary disease;

Dentistry - prevention of complications in the postoperative period during extraction of teeth, purulent-inflammatory diseases of the maxillofacial region, rehabilitation and recovery after surgical interventions in the maxillofacial area, improvement of implant integration, osteosynthesis.


Individual intolerance of the drug components;

Congenital or acquired coagulation disorders;


With caution: conducting hemodialysis (after consulting a doctor).

Application in pregnancy and breastfeeding

Take the drug with caution after consulting a doctor.

Side effects

The drug is well tolerated by patients. In some cases, there may be more frequent stools, a change in the consistency and odor of the stool, which quickly stop when the dosage is temporarily reduced. Occasionally, an allergic reaction may occur (skin rash, itching), which disappears after a dose reduction or drug withdrawal. If the conditions of application of the drug are violated, nausea, swelling and pains in the abdomen, headache, dizziness, exanthema, general weakness, sensation of fullness of the intestine may occur. These conditions disappear after a decrease in dosage or a temporary discontinuation of the drug.


There were no incidents of incompatibility with other drugs. The use of the drug together with antibiotics increases the effectiveness of antibiotic therapy. When used with hormones, the drug reduces the risk of thrombosis.

Dosing and Administration


Take at least 30 minutes before eating, without biting, washing with water (200 ml). After the operation, the drug is recommended to be taken from the 2-3rd day.

Treatment. The drug is taken after trauma and surgery or acute inflammation for the cleavage and removal of damaged tissues, resorption of hematomas, improvement of trophic tissue and repair processes, reducing inflammation and edema, reducing the risk of complications - thrombosis, development of adhesions, keloid scar formation and suppuration: 3 Table. 3 times a day for 2 weeks. If necessary, to improve recovery and healing, the course of taking the drug can be prolonged up to 4 weeks or more for 2 tablets. 3 times a day.

Prevention of complications. To prevent long-term consequences after surgery - thromboembolic complications, development of adhesive disease of the abdominal cavity, trophic disorders during prolonged bed rest and immobilization of the patient: the drug is recommended to take a long course in a dosage of 2 tablets. 3 times a day for 4 weeks or more or for the entire period of immobilization.

Use with antibiotics. When prescribing antibiotics, the drug is used to increase the effectiveness of antibiotic therapy and to reduce the undesirable effects of antibiotics. The drug is recommended to be taken throughout the course of antibiotic therapy according to 2 tablets. 3 times a day.

Use with hormones. When appointing long courses of hormones, the drug is recommended to reduce the risk of complications (thrombosis) by 2 tablets. 3 times a day during the entire course of taking hormonal drugs. When prescribing hormone replacement therapy to reduce the risk of thrombosis of the veins of the lower limbs, the drug is recommended to take 2 tablets. 3 times a day by repeated courses for 2 weeks with breaks of 3 weeks 3-4 times a year.

Prevention. To prevent thrombosis of the veins of the lower extremities and reduce the risk of vascular accidents (infarction), the drug is recommended to take 2 tablets. 3 times a day for at least 3-4 weeks, repeating the course of taking the drug 3-4 times a year.

Changing the course and dosages of the drug is recommended after consultation with your doctor.


Cases of drug overdose are unknown.

Special instructions

In the case of infectious processes, PHLoGENZYM does not replace antibiotics.

In case of an exacerbation of the underlying disease, a temporary reduction in the dose of the drug or temporary withdrawal of the drug after consultation with the doctor is recommended when taking the drug.

Patients suffering from diabetes should take into account that each tablet contains 0.015 XE.

Influence on the ability to drive a car or perform work that requires an increased speed of physical and mental reactions. The drug is not doping, does not have a negative impact on driving and performance of work requiring a high rate of mental and physical reactions.

Release Form

Tablets coated with enteric coating: in PVC blisters / aluminum foil of 20 pcs .; In vials of LDPE for 800 pcs .; In a pack of cardboard 2, 5 or 10 blisters.


Mukos Emulsions GmbH.

D-13509, Mirausstrasse, 17, Berlin, Germany.

for MUKOS Pharma GmbH & Co., KG.

D-13509, Mirausstrasse, 17, Berlin, Germany.

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Phlogenzym

In a dry place, at a temperature of 15-25 C.

Keep out of the reach of children.

Shelf life of the drug Phlogenzym

3 years.

Do not use after the expiry date printed on the package.

Someone from the United Kingdom - just purchased the goods:
Stamakort 20 capsules